Evolus (NASDAQ:EOLS) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Evolus (NASDAQ:EOLS) in a report issued on Thursday morning, Benzinga reports. HC Wainwright currently has a $27.00 target price on the stock. HC Wainwright also issued estimates for Evolus’ Q4 2024 earnings at $0.01 EPS, FY2026 earnings at $0.40 EPS, FY2027 earnings at $1.31 EPS and FY2028 earnings at $2.18 EPS.

EOLS has been the subject of several other research reports. Barclays boosted their price objective on shares of Evolus from $16.00 to $20.00 and gave the stock an overweight rating in a research report on Friday, September 13th. Cantor Fitzgerald restated an overweight rating on shares of Evolus in a research report on Monday, September 16th. Finally, Needham & Company LLC reiterated a buy rating and issued a $22.00 price target on shares of Evolus in a report on Friday, September 13th.

Evolus Price Performance

Shares of EOLS stock opened at $16.34 on Thursday. Evolus has a 52 week low of $7.44 and a 52 week high of $17.70. The stock has a market capitalization of $1.02 billion, a PE ratio of -15.56 and a beta of 1.31. The company has a debt-to-equity ratio of 6.26, a quick ratio of 2.67 and a current ratio of 2.92. The stock’s fifty day moving average is $15.13 and its 200-day moving average is $13.27.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The business had revenue of $66.91 million for the quarter, compared to analysts’ expectations of $65.06 million. Equities research analysts expect that Evolus will post -0.64 EPS for the current fiscal year.

Insider Activity

In related news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the sale, the chief financial officer now owns 148,502 shares in the company, valued at approximately $2,224,559.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CFO Sandra Beaver sold 3,276 shares of Evolus stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the transaction, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the sale, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at $1,305,643.75. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by company insiders.

Institutional Trading of Evolus

Several hedge funds have recently added to or reduced their stakes in EOLS. Perceptive Advisors LLC increased its holdings in shares of Evolus by 166.8% in the fourth quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock worth $41,735,000 after acquiring an additional 2,477,623 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Evolus by 5,627.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock worth $10,276,000 after purchasing an additional 930,566 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in Evolus during the 1st quarter worth approximately $11,628,000. BNP Paribas Financial Markets lifted its stake in Evolus by 84.2% in the first quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company’s stock valued at $5,683,000 after buying an additional 185,532 shares in the last quarter. Finally, Armistice Capital LLC acquired a new position in shares of Evolus in the second quarter valued at approximately $3,906,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.